Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.
On September 30, it was revealed in an SEC filing that John L Higgins, Director at Bio-Techne (NASDAQ:TECH) executed a significant exercise of company stock options. What Happened: A Form 4 filing with the U.S.
Detailed price information for Lennox International (LII-N) from The Globe and Mail including charting and trades.
Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The German group is paying $73 a share in cash, valuing the business at about $11.3 billion including debt. They also voted down the executive compensation proposal attached to the deal, which is an unusual pairing. […]
Robert V Baumgartner, Board Member at Bio-Techne (NASDAQ:TECH), reported a large exercise of company stock options on September 24, according to a new SEC filing. What Happened: In an insider options exercise disclosed
Bio-Techne has outperformed the Nasdaq over the past year, but analysts are cautious about the stock’s prospects.
Merck KGaA (XTRA:MRK) has received shareholder approval from Bio-Techne investors for its planned acquisition of the US life sciences group. The vote clears a major corporate hurdle in the transaction process, with completion still subject to remaining regulatory reviews. The planned merger is expected to broaden the combined product set and customer reach across multiple stages of the life sciences workflow. The Bio-Techne shareholder approval is important, but it should not be the only...
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of its new Customer Experience Center in Düsseldorf, Germany, a flagship facility designed to bring European customers closer to Bio-Techne's latest innovations and scientific expertise.
Bio-Techne (TECH) has drawn fresh attention after recent trading left the share price at $72.27, with performance over the past month roughly flat and the past 3 months showing a strong double digit gain. Recent trading tells a mixed story for Bio-Techne. The share price return of 29% over the past 90 days sits alongside a 1-year total shareholder return of 41%, while the 5-year total shareholder return shows a decline of 44%. This hints that momentum has only recently improved following a...
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro
500-Page Report Ranks Suppliers by Competitive Position Across the Company Evaluation Matrix as Infectious Disease Testing Drives the Largest Application Segment IVD Raw Material Market IVD Raw Material Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "IVD Raw Material Market by Product Type, Technology, Application, Supply Source, Origin, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. The global in vitro diagnostics (IVD) raw material market is pro
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Bio-Techne (NASDAQ:TECH) and its peers.
This is the newest page. Registered accounts read further back.